Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009

References 

1. Feldman TE. Analysis of outcomes after repeat revascularization: analysis from the SYNTAX trial. Transcatheter Cardiovascular Therapeutics 2009, September 22, 2009, San Francisco, California.
2. Morice M. Contemporary indications for left main stenting: new insights from SYNTAX. Transcatheter Cardiovascular Therapeutics 2009, September 23, 2009, San Francisco, California.
3. Nadra I. Does the SYNTAX score predict outcome following PCI to the left main coronary artery in the real world? Transcatheter Cardiovascular Therapeutics 2009, September 22, 2009, San Francisco, California.
4. Chieffo A. Five year outcomes following PCI with DESimplantation vs CABG for unprotected LMCA lesions: Milan experience. Transcatheter Cardiovascular Therapeutics 2009, September 22, 2009, San Francisco, California.
5. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:93
6. Bhatt D. The COGENT trial. Transcatheter Cardiovascular Therapeutics 2009, September 23, 2009, San Francisco, California.
7. Mehta S.CURRENT OASIS 7: A 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. European Society of Cardiology 2009 Scientific Sessions, August 30, 2009, Barcelona, Spain.
8. Mehta S.CURRENT-STEMI PCI: doubledose vs standard dose clopidogrel in ACS patients undergoing PCI for STEMI. Transcatheter Cardiovascular Therapeutics 2009, September 24, 2009, San Francisco, California.
9. Cannon C. PLATO-Invasive: ticagrelor compared with clopidogrel in patients with acute coronary syndromes–the Platelet Inhibition and Patient Outcomes Trial. Transcatheter Cardiovascular Therapeutics 2009, September 24, 2009, San Francisco, California.
10. Kappetein AP. Coronary revascularization in diabetic patients. Transcatheter Cardiovascular Therapeutics 2009, September 25, 2009, San Francisco, California.
11. Wimmer-Greinecker G. Coronary revascularization in elderly patients. Transcatheter Cardiovascular Therapeutics 2009, September 25, 2009, San Francisco, California.
12. Byrne JG. Hybrid revascularization: can it be cost effective? Transcatheter Cardiovascular Therapeutics 2009, September 24, 2009, San Francisco, California.
13. Poston R. Hybrid revascularization: simultaneous vs staged early vs staged delayed. Transcatheter Cardiovascular Therapeutics 2009, September 24, 2009, San Francisco, California.
14. Mehran R. IMA angiography soon after CABG: findings and when to intervene. Transcatheter Cardiovascular Therapeutics 2009, September 24, 2009, San Francisco, California.
15. Argenziano M. Minimally invasive mitral valve surgery: transferring the pain from the patient to the surgeon. Transcatheter Cardiovascular Therapeutics 2009, September 23, 2009, San Francisco, California.
16. Dowling RD. Emerging LVAD technologies. Transcatheter Cardiovascular Therapeutics 2009, September 23, 2009, San Francisco, California.